Before we launched Drug Ratings in May of 2017, 52 percent of doctors polled felt they did not have all the information they would want about a drug before prescribing, and 91 percent thought that pharmaceutical marketing ‘spins’ – misrepresents, omits, or otherwise adjusts – information about drugs to show them in a more positive light.
Drug Ratings gives physicians a clinical decision support tool in which they can research, rate, and share their direct experience on the efficacy, safety, tolerability, accessibility, and adherence of specific drugs in real time. The ability to help their peers prescribe the most effective and safe drugs, is one of the primary reasons why we decided to create Drug Ratings. Statistics support the importance of peer influence in medicine. A poll of more than 2,900 SERMO physicians found that 83 percent reported that the opinion or feedback of a fellow physician has changed their perception of a drug. Further, 80 percent trust recommendations of a very large number of doctors with real-world experience with a drug, over the recommendations of a small number of key opinion leaders and academics.  Underscoring physicians’ trust in the system, 84 percent believe Drug Ratings will lead to better patient outcomes.
The early success of Drug Ratings highlights its importance to the physician community. Here’s a snapshot of how quickly it has grown:
Since we released Drug Ratings, it has received significant media attention from outlets such as Becker’s Spine Review, HIT Consultant, INTOUCH Solutions, SA Breaking News, FiercePharma, MedCity News, mHealthWatch, and more. Drug Ratings even won an award for innovation!
When it comes to drugs, official clinical trial data and product monographs are one half of the story; commentary and reviews are the other half. Combined with official sources of information, SERMO Drug Ratings offers a more holistic and deeper way to evaluate drugs, and can help doctors make more informed prescribing decisions. We want to make it as easy as possible for doctors to navigate and find the right drugs for their patients.
Drug Ratings was developed by SERMO and SERMO physicians. The statistical methodology behind Ratings was developed and verified independently by biostatistics consultants led by Lee-Jen Wei of the Blue Null Consulting Group.
 SERMO poll of 2,918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.
 SERMO poll of 2017 doctors from the U.S., Italy, the U.K., France, Canada, Brazil, Belgium, Poland, Sweden, Korea, Switzerland, Colombia, Israel, Japan, and South Africa. It was fielded in October 2017. The margin of error for this poll is ±2%.